Comparing the current results to its competitors, Immunovant Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, slower than the combined decrease of the IMVT's competitors by -54.72 %, recorded in the same quarter.
Immunovant Inc 's Comment on Competition and Industry Peers
The company anticipates that IMVT-1402 will achieve approximately 80% IgG reductions with weekly dosing. In Phase 1 trials, IMVT-1402 demonstrated minimal off-target effects. Development of batoclimab was discontinued after Phase 3 trials failed to meet primary endpoints. The company intends to apply insights from batoclimab to the advancement of IMVT-1402. Data from batoclimab in indications such as myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) support the potential for IMVT-1402 to provide improved efficacy with convenient administration. Additionally, data from a competitor in Sjögren’s disease (SjD) support the potential for IMVT-1402 to offer favorable efficacy and safety. The company aims to position IMVT-1402 as nearly first and best-in-class in indications including SjD and plans to evaluate additional indications based on unmet medical need and commercial potential.
December 20, 2023
NEW YORK, Dec. 20, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to enhancing the quality of life for individuals with autoimmune diseases, has made a groundbreaking breakthrough with its drug, batoclimab. The initial data from a 24-week Phase 2 clinical trial has unveiled extraordinary results, showcasing response rates surpassing 50%, in patients suffering from Graves disease.Graves disease is an autoimmune disorder that primarily affects the thyroid, resulting in hyperthyroidism, a condition where the thyroid gland overproduces thyroid hormones. This excess production leads to various debilitating symptoms, including rapid weight loss, irregular heartbeat, insomnia,...
Dbv Technologies S.A.'s business model focuses on developing and commercializing novel therapies using its proprietary Viaskin technology platform, which aims to desensitize patients with food allergies.
Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.
Palisade Bio Inc is a biopharmaceutical company that focuses on developing and commercializing treatments for gastrointestinal diseases by leveraging its proprietary microbiome platform. Their business model centers around conducting research and development to create novel therapeutics and bringing them to market through strategic partnerships and collaborations in the healthcare industry.
Plus Therapeutics Inc is a biotechnology company that focuses on developing precision nanoparticles for targeted therapy. They utilize their proprietary technology to create and commercialize innovative drugs for the treatment of cancer and other diseases.
Sources:
Immunovant Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immunovant Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
